Mandi Allen-Bell, MD
Family Medicine · Scottsboro, ALNPI 1215088026
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,138 of the $19,777 with a category attached, or 86.7%. AbbVie accounts for 95.4% of it on its own, with 14 other manufacturers making up the rest. Among family medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $102.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$19K
- Novo Nordisk$276
- Lilly USA, LLC$215
- Amgen$77
- AstraZeneca$55
- Smith+Nephew$53
- plus $239 from 9 others
What the payments were for
- Speaking & faculty fees$17,13887%
- Food & beverage$2,63913%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 139 | $18,863 |
| Novo Nordisk | 19 | $276 |
| Lilly USA, LLC | 13 | $215 |
| Amgen | 3 | $77 |
| AstraZeneca | 4 | $55 |
| Smith+Nephew | 1 | $53 |
| Novartis | 3 | $52 |
| GSK | 3 | $49 |
| Abbott | 2 | $42 |
| Bayer | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Pfizer | 1 | $13 |
| Antares Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$146
How this compares
$19,777 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $71,237 |
| JardianceEmpagliflozin | 49 | $53,147 |
| MounjaroTirzepatide | 40 | $40,219 |
| EliquisApixaban | 39 | $31,354 |
| JanuviaSitagliptin Phosphate | 42 | $22,535 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $20,692 |
| TrulicityDulaglutide | 17 | $15,766 |
| BelsomraSuvorexant | 17 | $10,513 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $10,098 |
| Gvoke Hypopen 1-PackGlucagon | 12 | $9,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,676 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 242 | $4,786 |
| Atorvastatin Calcium | 307 | $4,291 |
| Levothyroxine Sodium | 278 | $3,471 |
| Pantoprazole Sodium | 293 | $3,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $276 | $71,23770 claims |
| Lilly USA, LLCMounjaro, Trulicity | $215 | $55,98457 claims |
| PfizerEliquis | $13 | $31,35439 claims |
| GSKTrelegy Ellipta | $49 | $7,67612 claims |
| AstraZenecaSymbicort | $55 | $2,48811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Scottsboro
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Philip WilsonDothan$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.